Roche announces new, four-year data from RHONE-X extension study

Genentech, a member of the Roche Group, announced new, four-year data from the RHONE-X extension study. The study met all primary endpoints, showing that Vabysmo was well tolerated in people with diabetic macular edema, or DME, who received treatment for up to four years. Exploratory results from the long-term study showed that Vabysmo continued to preserve vision, dry retinal fluid that can impair sight and allow extended time between treatments in people with DME. These data were presented in a late-breaking oral presentation at the American Society of Retina Specialists, or ASRS, 2024 Annual Meeting in Stockholm, Sweden. “These four-year data build on our pivotal studies and reinforce Vabysmo’s potential to become standard of care treatment for diabetic macular edema, which affects 29 million people worldwide. We are especially pleased to see that 9 out of 10 patients showed no sign of DME after four years of treatment with Vabysmo, which is an incredible long-term outcome for people living with this condition,” said Levi Garraway, M.D., Ph.D., Genentech’s chief medical officer and head of Global Product Development.